Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

What Was Tested

This randomized controlled trial looks at Naphthalenes in the context of hyperparathyroidism.

Management of secondary hyperparathyroidism is challenging with traditional therapy.

Who Took Part

The abstract describes 395 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The patients were allocated by chance, so the Naphthalenes group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Naphthalenes, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Naphthalenes group a baseline to be compared against.

Running at several centres spread the Naphthalenes study over different clinics and patient groups.

What Was Measured

Management of secondary hyperparathyroidism is challenging with traditional therapy.

Topics PubMed links to this paper include Calcium, Cinacalcet, Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Naphthalenes, Parathyroid Hormone and Peritoneal Dialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Naphthalenes in 395 patients in people with hyperparathyroidism.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2005 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: Hyperparathyroidism research.